Безопасен ли rh-oligopeptide-1 при беременности?
No harmonised CLP classification (ECHA Annex VI) or SCCS/CIR reproductive safety restriction identified. However, as a peptide growth factor (EGF family) there is a theoretical class-based concern about mitogenic activity relevant to developing tissues; no animal or human reproductive toxicity data were identified to confirm hazard (sources searched: ECHA Annex VI, SCCS/CIR, PubMed, PubChem/CosIng, EWG). Topical systemic absorption for large peptides like rhEGF is expected to be negligible, so direct systemic exposure in pregnancy is unlikely.
Pregnancy-safe products containing rh-oligopeptide-1









Related ingredients
Frequently asked questions
- Безопасен ли rh-oligopeptide-1 при беременности?
- No harmonised CLP classification (ECHA Annex VI) or SCCS/CIR reproductive safety restriction identified. However, as a peptide growth factor (EGF family) there is a theoretical class-based concern about mitogenic activity relevant to developing tissues; no animal or human reproductive toxicity data were identified to confirm hazard (sources searched: ECHA Annex VI, SCCS/CIR, PubMed, PubChem/CosIng, EWG). Topical systemic absorption for large peptides like rhEGF is expected to be negligible, so direct systemic exposure in pregnancy is unlikely.
- Безопасен ли rh-oligopeptide-1 при грудном вскармливании?
- Same rationale as pregnancy: theoretical concern from growth-factor activity if systemically absorbed, but no evidence of reproductive or lactation-specific toxicity or breast milk transfer. Large peptide size and available topical formulations suggest negligible systemic bioavailability after topical cosmetic use (sources: PubMed, PubChem, CosIng, EWG).
- Безопасен ли rh-oligopeptide-1 для кожи малыша?
- Hazard and mechanism scores unchanged (no infant-specific data showing reproductive/ developmental toxicity). Exposure score increased by +1 because infant skin has a less mature barrier and higher surface-area-to-weight ratio; if the peptide has any measurable percutaneous uptake the relative exposure in 0–3 yr olds would be higher. No studies demonstrating placental/breastmilk transfer or infant adverse outcomes were found (sources: PubMed, CosIng, PubChem, EWG).
- Как VeriMom оценивает rh-oligopeptide-1?
- VeriMom оценивает rh-oligopeptide-1 в 73/100 (низкий риск) на основе EU CosIng, классификаций ECHA и исследований PubMed.
- Какие безопасные альтернативы rh-oligopeptide-1 при беременности?
- См. наш список безопасных альтернатив rh-oligopeptide-1 с аналогичной функцией и классификацией без известных рисков.
Проверь любой состав за 2 секунды
Скачай VeriMom бесплатно — отсканируй любой продукт и мгновенно получи оценку безопасности при беременности.
Медицинская оговорка
Данная информация предоставлена исключительно в образовательных целях и не является медицинской рекомендацией. Оценки безопасности основаны на общедоступных данных и могут не отражать все риски. Всегда консультируйтесь с вашим врачом перед использованием любых средств во время беременности или грудного вскармливания.